The Alcoholic Hepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Alcoholic Hepatitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcoholic Hepatitis Market.
Some of the key takeaways from the Alcoholic Hepatitis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Alcoholic Hepatitis treatment therapies with a considerable amount of success over the years.
- Alcoholic Hepatitis companies working in the treatment market are ImmuneMed, NEXEL, Surrozen, Seal Rock Therapeutics, Intercept Pharmaceuticals, Aldeyra Therapeutics, Novartis, and others, are developing therapies for the Alcoholic Hepatitis treatment
- Emerging Alcoholic Hepatitis therapies in the different phases of clinical trials are- Burfiralimab, NP-011, SZN 043, SRT-015, INT 787, ADX 629, Canakinumab, and others are expected to have a significant impact on the Alcoholic Hepatitis market in the coming years.
- In December 2022, A Phase 2a randomized double-blind placebo-controlled multicenter proof-of-concept study evaluating the safety, tolerability, efficacy, and pharmacokinetics of INT-787 in subjects with severe alcohol-associated hepatitis was started by Intercept Pharmaceuticals.
- In November 2022, The next generation FXR agonist, INT-787, is being developed by Intercept Pharmaceuticals with the intention of concentrating on treating severe alcohol-associated hepatitis (sAH). At the American Association for the Study of Liver Diseases (AASLD) annual meeting in Washington, D.C., preliminary data from Intercept's Phase I trial of INT-787 in healthy subjects were presented. These data supported a favorable safety and tolerability profile for INT-787 in healthy male and female adults.
Alcoholic Hepatitis Overview
An immediate symptom of alcoholic liver disease is alcoholic hepatitis. Excessive alcohol consumption can cause hepatic inflammation, which can manifest clinically as liver failure, coagulopathy, encephalopathy, and jaundice. This condition can worsen and lead to multiorgan failure with a high death rate.
Get a Free Sample PDF Report to know more about Alcoholic Hepatitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/alcoholic-hepatitis-pipeline-insight
Emerging Alcoholic Hepatitis Drugs Under Different Phases of Clinical Development Include:
- Burfiralimab: ImmuneMed
- NP-011: NEXEL
- SZN 043: Surrozen
- SRT-015: Seal Rock Therapeutics
- INT 787: Intercept Pharmaceuticals
- ADX 629: Aldeyra Therapeutics
- Canakinumab: Novartis Pharmaceuticals
Alcoholic Hepatitis Route of Administration
Alcoholic Hepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Alcoholic Hepatitis Molecule Type
Alcoholic Hepatitis Products have been categorized under various Molecule types, such as
- Monoclonal antibody
- Small molecule
- Peptide
Alcoholic Hepatitis Pipeline Therapeutics Assessment
- Alcoholic Hepatitis Assessment by Product Type
- Alcoholic Hepatitis By Stage and Product Type
- Alcoholic Hepatitis Assessment by Route of Administration
- Alcoholic Hepatitis By Stage and Route of Administration
- Alcoholic Hepatitis Assessment by Molecule Type
- Alcoholic Hepatitis by Stage and Molecule Type
DelveInsight's Alcoholic Hepatitis Report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Alcoholic Hepatitis product details are provided in the report. Download the Alcoholic Hepatitis pipeline report to learn more about the emerging Alcoholic Hepatitis therapies
Some of the key companies in the Alcoholic Hepatitis Therapeutics Market include:
Key companies developing therapies for Alcoholic Hepatitis are - DURECT Corp, Evive Biotech, Hepatx Corp, ImmuneMed Inc, Intercept Pharmaceuticals Inc, Novartis AG, Odan Laboratories Ltd, Pattern Therapeutics, PharmaKing Co Ltd, and Rejuvenation Technologies Inc, and others.
Alcoholic Hepatitis Pipeline Analysis:
The Alcoholic Hepatitis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Alcoholic Hepatitis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alcoholic Hepatitis Treatment.
- Alcoholic Hepatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Alcoholic Hepatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alcoholic Hepatitis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alcoholic Hepatitis drugs and therapies
Alcoholic Hepatitis Pipeline Market Drivers
- Increase in prevalence of alcohol related diseases, development of new strategies and viable treatment options for alcoholic hepatitis management are some of the important factors that are fueling the Alcoholic Hepatitis Market.
Alcoholic Hepatitis Pipeline Market Barriers
- However, lack of therapies to treat severe alcoholic hepatitis, complications associated with the disease and other factors are creating obstacles in the Alcoholic Hepatitis Market growth.
Scope of Alcoholic Hepatitis Pipeline Drug Insight
- Coverage: Global
- Key Alcoholic Hepatitis Companies: ImmuneMed, NEXEL, Surrozen, Seal Rock Therapeutics, Intercept Pharmaceuticals, Aldeyra Therapeutics, Novartis, and others
- Key Alcoholic Hepatitis Therapies: Burfiralimab, NP-011, SZN 043, SRT-015, INT 787, ADX 629, Canakinumab, and others
- Alcoholic Hepatitis Therapeutic Assessment: Alcoholic Hepatitis current marketed and Alcoholic Hepatitis emerging therapies
- Alcoholic Hepatitis Market Dynamics: Alcoholic Hepatitis market drivers and Alcoholic Hepatitis market barriers
Request for Sample PDF Report for Alcoholic Hepatitis Pipeline Assessment and clinical trials
Table of Contents
1. Alcoholic Hepatitis Report Introduction
2. Alcoholic Hepatitis Executive Summary
3. Alcoholic Hepatitis Overview
4. Alcoholic Hepatitis- Analytical Perspective In-depth Commercial Assessment
5. Alcoholic Hepatitis Pipeline Therapeutics
6. Alcoholic Hepatitis Late Stage Products (Phase II/III)
7. Alcoholic Hepatitis Mid Stage Products (Phase II)
8. Alcoholic Hepatitis Early Stage Products (Phase I)
9. Alcoholic Hepatitis Preclinical Stage Products
10. Alcoholic Hepatitis Therapeutics Assessment
11. Alcoholic Hepatitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Alcoholic Hepatitis Key Companies
14. Alcoholic Hepatitis Key Products
15. Alcoholic Hepatitis Unmet Needs
16 . Alcoholic Hepatitis Market Drivers and Barriers
17. Alcoholic Hepatitis Future Perspectives and Conclusion
18. Alcoholic Hepatitis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
